ABBV Options Signal Bullish Bias: Key Strike Levels and Trading Setups for Dec 19 Expiry

Generated by AI AgentOptions FocusReviewed byAInvest News Editorial Team
Tuesday, Dec 16, 2025 1:38 pm ET1min read
Aime RobotAime Summary

-

trades at $222.43, down 2.2% from its 52-week high, with heavy call buying at $240–$250 (OI: 20,975) signaling rebound bets.

- Q3 earnings beat and a $1.73/share dividend boost optimism, but BofA cuts price target to $233 amid a 172 P/E valuation concern.

- Puts at $185 (OI: 3,403) and a 0.77 put/call ratio highlight cautious bullish sentiment, though downside risks persist below $220 support.

- Traders advised to consider call spreads ($230–$240) or $220 put hedges, with key levels at $225 (support) and $230 (block trade trigger).

  • ABBV trades at $222.43, down 2.2% from its 52-week high of $227.45
  • Call open interest dominates at $240 and $250 strikes (OI: 16,889 and 4,086), while puts pile up at $185 (OI: 3,403)
  • Q3 earnings beat and dividend hike support long-term optimism, but BofA cuts price target to $233

The options market is whispering a story of cautious optimism. Despite today’s pullback, heavy call buying at $240 and $250 suggests institutional players are hedging for a rebound. Let’s break down what this means for your strategy.Bullish Sentiment at $240–$250, But Downside Risks Lurk

The call open interest at $240 (

) and $250 () is massive—over 20,000 contracts combined. That’s not just noise; it’s a bet that will reclaim its 52-week high by Friday. But here’s the twist: the stock is currently 13% below $240. For those calls to pay off, ABBV needs a sharp reversal.

Meanwhile, the $185 put (

) has 3,403 open contracts, hinting at a floor if the sell-off accelerates. The put/call ratio of 0.77 (calls > puts) leans bullish, but don’t ignore the block trade at ABBV20251017C230—6,138 contracts traded at $230. That’s a whale-sized bet on a rebound, not a crash.

Earnings Beat and Pipeline Hype vs. Valuation Concerns

AbbVie’s Q3 beat and dividend raise ($1.73/share) are solid, but BofA’s $233 target cut reflects reality: the stock trades at a 172 P/E, way above its 5-year average. Analysts love the pipeline (Rinvoq expansions, tavapadon), but those won’t boost the stock overnight. Institutional buyers (Shorepoint, GAMMA) are piling in, but retail traders should ask: Is this a "buy the rumor" play or a "sell the news" trap?

Actionable Trades for ABBV: Calls, Puts, and Precision Entries
  1. Call Spread for Dec 19: Buy (in-the-money) and sell ABBV20251219C240. If ABBV holds above $225, the $230–$240 range could capture a rebound while capping risk.
  2. Put Hedge for Long-Term Holders: Buy (next Friday’s expiry) at $220. If ABBV dips below $222, this put acts as insurance against a gap down.
  3. Stock Entry at $220–$222: Use Bollinger Band support ($220.14) as a buy zone. Target $225 first (30D support level), then $230 (block trade level). Exit if it breaks $217.50.

Volatility on the Horizon

ABBV is caught between a rock (high valuation) and a hard place (pipeline optimism). The options data leans bullish, but don’t ignore the puts at $185–$200—they’re a warning sign. If the stock holds above $220, this could be a short-term buying opportunity. But if it cracks $217.50, brace for a test of the 200D MA at $205.22. Either way, the next 72 hours will clarify whether this is a rebound or a breakdown.

Comments



Add a public comment...
No comments

No comments yet